Summary:
In males with erythrocytosis, canagliflozin significantly increased the risk of thromboembolic events compared to placebo, though it was not associated with increased thromboembolic events in females.
| PICO | Description |
|---|---|
| Population | Males with erythrocytosis and preexisting cardiovascular risk enrolled in the Canagliflozin Cardiovascular Assessment Study program. |
| Intervention | Canagliflozin (dosage not specified, SGLT2 inhibitor). |
| Comparison | Placebo group in randomized, double-blind, placebo-controlled trials. |
| Outcome | Canagliflozin use in males with erythrocytosis significantly increased thromboembolic risk when compared to placebo. No significant differences were observed in females. |
Source: Yohei Doi, et al. “Canagliflozin may increase thromboembolic events in males with erythrocytosis but not in females.” Read article here.
